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REVIEWStrategies for Drug Encapsulation and Controlled
Delivery Based on Vapor-Phase Deposited Thin FilmsAlberto Perrotta, Oliver Werzer, and Anna Maria Coclite*Vapor-phase deposition methods allow the synthesis and engineering of
organic and inorganic thin films, with high control on the chemical
composition, physical properties, and conformality. In this review, the recent
applications of vapor-phase deposition methods such as initiated chemical
vapor deposition (iCVD), plasma enhanced chemical vapor deposition
(PE-CVD), and atomic layer deposition (ALD), for the encapsulation of active
pharmaceutical drugs are reported. The strategies and emergent routes for
the application of vapor-deposited thin films on the drug controlled release
and for the engineering of advanced release nanostructured devices are
presented.1. Introduction
Drug therapies require the active pharmaceutical ingredients
(API) to reach the desired site of action and the success of the
treatment is governed by the time the drug requires to reach the
target, the amountofdrugassemblingat the target site aswell as its
residence time. Furthermore, considerations like administration
route,[1–3]processing,[4,5] andstorageofdrugformulations[5,6]need
attention as only the combination of all these allows the
achievement of successful medications ready for therapy,
marketing, and help for patients. Very often, drug molecules well
perform only when assistance from other substances is provided.
These substances (i.e., excipients) limit processing issues,[7]
mechanical and chemical instabilities,[8] dissolution problems,[9]
resorptionproblems,[10] andpoorbio-availabilityor assist for better
systemic circulation.[11] Hence, the development of new therapeu-
tic options is not limited to the synthesis and screening of new
APIs, but also different administration routes and alternative
dosage forms are extensively investigated. Generally, the latter is
achieved by the engineering and processing of new excipients.
Ever sincemedications were used, excipients are employed.[12,13]
Especially, the usage ofmacromolecules or polymers[14–16] asﬁllers,
gliding agent, disintegration agent, or protective coatings allow theDr. A. M. Coclite, Dr. A. Perrotta
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tablets,[17] pellets,[18] or powders. Develop-
ments in nanomaterial chemistry have
enabled the proliferation of different types
of drug carriers, for example, polymer–drug
conjugates, nanoparticles, nanoclusters,
micelles, dendritic polymer carriers, nano-
capsules, and nanoemulsions.[19,20] These
can work as scaffolds in which the drug is
loaded and preserved until delivery. The
delivery can be spatio-temporally controlled
to minimize side effects and maximize,
instead, the therapeutic efﬁcacy.[21] Recently
alsometal-organic frameworks (MOF) (called
also coordination polymers) have shown
interesting results as drug carriers.[22,23]MOFs have very large and highly controlled porosity that can be
used for loading and releasing the drug molecules. Solutions,
dispersions, or emulsions of nanostructured materials conjugated
with drugs hardly perform without large molecular weight species
whichprovide, amongstothers, solubility enhancement,[24] viscosity
adjustment, and stability.[25] Another drawback of encapsulating
drugs into nanocarriers is that only limited loads ofmedicine canbe
hosted, therefore multiple injections are required during a
treatment cycle to deliver an optimal dose of drug to the desired site.
Alternatively, hydrogels andmore generally polymers can offer
interesting solutions that are more effective for long-term
treatments.[26,27] In this perspective, natural derived products like
cellulose derivatives or gums[28] are well established and approved
to be used in medications.[25] However, with progress in polymer
chemistry, more synthetic counterparts with well-deﬁned struc-
tures, narrow molecular weight distributions, and tunable
properties are ready to be commercialized, enabling even more
sophisticatedmedications.[29] In this regard, polymers enabledrug
formulation functions like protection against premature release,
and the stabilization of speciﬁc solid state forms. Furthermore,
their potential for realization of site-speciﬁc drug release and
activityareofparamount importance.[30–33]Drug-loadedhydrogels
canbe directly injected in aminimally invasiveway, thanks to their
highmoldability, andtheability to formtissueconstructs insitu.[34]
Particularly interesting is the use of external stimuli to trigger the
release of the drug at a speciﬁc site or speciﬁc time.[35–37]1.1. Polymers as API Carriers: Strategies and Diffusion
Mechanisms
To date, only a limited number of products are available which
make use of a pure polymer to achieve therapeutic actions[38,39];
examples of such polymer therapeutics are Copaxone
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. More common are instead drug-
polymer conjugates, which can host other molecular species
within the polymer backbone,[40,41] either physisorbed or
covalently bonded. For liquid drug formulations or fabrication
processes, polymers are also used to adjust speciﬁc properties
like viscosity, or enhance solubility, or stability. In addition,
polymers also assist in fabricating more sophisticated or even
smart drug release forms.[42–46] As an example, having polymers
of amphiphilic character, a polar and an apolar phase can be kept
separated, so that the drug is encapsulated within the apolar
phase. Such polymeric vehicles, similar to small moleculesAdv. Eng. Mater. 2017, 1700639 1700639 (2counterparts made from lipids or others, often provide enhanced
drug stability.[45] More importantly, such vehicles provide
eventually very deﬁned drug release capabilities, either due to
controlled diffusion or triggered by external stimuli like pH and
temperature change.[42–44,47,48]
When drug formulations are obtained from powders, they are
generally addressed as solid state forms, and include tablets or
pellets.Mostly, these are fabricated directly by compressing powder
mixtures of an API and a polymer(s) or employing granulation
routes. The high temperatures or pressures adopted in their
processing induce polymermelting,which allows the production of
solid state dispersions[49] or solid state solutions applicable in
standard extrusion[50] or injection molding processes.[51]
In any case, the API release from a drug polymer composite
or matrix formulations results from either degradation/erosion/
disintegration of the polymer host or by molecular diffusion
through the polymer host. For diffusion-limited drug release,
matrix-, reservoir-, and hydrogel-based systems are usually
differentiated. When the API is homogenously dispersed inside
a suitable host, made from materials such as cellulose or lipids,
the tortuosity of the matrix determines the drug release kinetics.
Hydrogel drug formulations[52,53] are similar to matrix systems
as they are usually loaded with the API, but the drug release
mechanism depends on swelling of the polymeric material and,
thus, it is governed by the matrix mesh size. Furthermore, a
reservoir-drug formulation is usually comprised of a core-shell
structure. In such, the API is encapsulated and so protected from
the dissolution medium by a deﬁned membrane which, on
proper engineering, enables controlled drug release.1.2. Polymer Synthesis: Emerging Routes
Polymer synthesis most often requires liquid environments and
a variety of approaches yield deﬁned homo-polymers, alternat-
ing, or statistical co-polymers of various monomers. Mora-
Huertas et al. have published an extensive review on the
preparation methods of polymer-based nanocapsules for drug
delivery: nanoprecipitation, emulsion–diffusion, double emulsi-
ﬁcation, emulsion-coacervation, polymer-coating, and layer-by-
layer.[44] Most of these are quite laborious and requiremany steps
for the drug encapsulation. In recent years, polymer syntheses
from vapor phase have become increasingly popular. Classically,
chemical vapor deposition (CVD) routes were based on the
fragmentation of speciﬁc precursor molecules by high temper-
atures. These are not suitable for the synthesis of polymer shells
around drugs, due to the possible degradation of thermosensi-
tive components, for example, oxidation of drug molecules.
Further developments provide now more advanced polymeric
vapor phase synthesis processes, which are known as initiated
chemical vapor deposition (iCVD),[54] plasma enhanced chemi-
cal vapor deposition (PE-CVD),[55] or self-limiting techniques,
such as atomic and molecular layer deposition (ALD and MLD,
respectively).[56,57] Each of these methods uses different
chemical routes for the synthesis of speciﬁc polymers/matrices
and, particularly, each method provides speciﬁc process-tunable
properties, for instance leading to signiﬁcantly lower synthesis/
reaction temperatures. One important advantage of polymer
synthesis routes from the vapor-phase is the absolute lack of© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 21)
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directly on the substrate as vapors. The elimination of the need to
dissolve the polymers facilitates the encapsulation of drugs by
avoiding the necessity of usingmultiple dissolution steps, avoids
unwanted drug dissolution andmixed interfaces. In addition, no
plasticizers, leachable, and surfactants are needed and this
eliminates the health considerations associated with these
components. The various vapor phase processes enable the
production of numerous different polymer thin ﬁlms with a
chemistry similar to the one obtained with classic synthesis
routes or leading to co-polymers with otherwise inaccessible
monomer combinations, since monomers with different
solubilities can be more easily copolymerized in dry processes.
Copolymers of hydrophobic and hydrophilic components, highly
crosslinked and ﬂuorinated polymers are just some examples of
the “unconventional” chemistries that are easily accessible by
vapor methods. From these, polymers and matrices could be
produced and applied in well-established processes for fabricat-
ing solid or liquid formulations, similarly to the classical
solution-processed methods. However, the slower polymer
processing of vapor-phase methods represents a hurdle for
the replacement of conventional up-scaled routes.
The possibility to synthesize excipients/matrices from vapor
phase processes enables alternative routes, distinct from
standard liquid, or solid state processes, allowing the develop-
ment of enhanced or even new functionalities in drug
formulations. For instance, a wet (spray) coating onto pellets
has an enhanced contact due to slight dissolution of the pellets at
the interface with the coating, possibly reducing the mechanical
stability of this solid state formulation. Contrary, in a vapor phase
process, the monomers/precursor molecules mainly adsorb/
chemisorb at the dry interface reducing potential complications
due to moisture increase.
Vapor processes allow also one to reproduce the geometry of
the substrate because the thickness uniformity can be controlled
at the nanoscale, also on grooves or microchannels, preserving
the original micro/nano-structuration. This property can be used
for engineering more complex devices based on nanostructured
conjugates of polymers and drugs.
A summary of the advantages offered by vapor deposition
methods is sketched in Figure 1. In this contribution, the current
state of vapor deposited polymer/matrix investigation in
pharmaceutical relevant environments and research is critically
reviewed. Notwithstanding the remarkable potential of these
techniques in exchanging excipients in standard processes, the
focus is to highlight current trends in the development of new
strategies for advanced drug encapsulation techniques aimed at
the control of the drug delivery in a variety of potential
applications.1.3. Toxicology and Approval
Regulatory approval is a major hurdle in the introduction of any
new substance within medications, cosmetics, or food and
should guarantee prevention from harm to living organisms and
the environment. Consequently, many tests need to be provided
making the market introduction a stage of potential high
commercial risk.[58,59] For this reason, companies andAdv. Eng. Mater. 2017, 1700639 1700639 (3developers aim at using already approved and well-established
materials for the generation of new formulations, as such
approval is of zero or much lower risk. For new approaches, for
example, comprising vacuum deposition techniques, the
improvement in functionality, and potential applications must
compensate for the potential risk to justify their usage, and up to
now their broad application in drug formulation is limited.
Nevertheless, the large spectrum of different chemistries allows
many differentmolecules to be combined which, in addition, can
positively inﬂuences the stages of approval. For instance, using
monomer units of potential low toxicity minimizes harm to
living organism. Biodegradable polymers[60,61] prevent problems
of material accumulation, given that the degenerated polymer
fragments are harmless. In vitro tests demonstrate that, in fact,
the cytotoxic impact of most polymeric layers is very low or even
absent.[52] While such tests are limited in estimating the behavior
in an extended in vivo environment where numerous biological
and chemical mechanisms are additionally involved, the initial
studies are very promising. This might even lead to the
conclusion that, with some uncertainty, with the adoption of
vapor-phase deposition processes of polymers, a very similar
margin of safety is accessible when compared to conventional
and more established polymeric systems.2. Vapor-Phase Deposition Methods
In order to achieve controlled drug encapsulation and delivery,
nanocomponents, hierarchical structures, and multilayers have
to be combined in intelligent devices. In this scenario, vapor
phase deposition methods, such as CVD and self-limited
processes, are very appealing because they give the possibility
of synthesizing polymer thin ﬁlms with engineered surface
properties, functionalities, and topography with high uniformity
and scalability.[62] A deep knowledge of the process allows the
tuning of the properties of the deposited polymer ﬁlms such as
chemical composition, geometry (i.e., conformality to (nano-)
structured substrates), morphology in terms of cross-linking and
crystallinity degrees, durability, and thermal stability. In this
review, three major vapor-phase deposition methods will be
discussed in terms of synthesis mechanism and applicability to
pharmaceutical environment, namely initiated CVD, plasma
enhanced-CVD and atomic/molecular layer deposition. Sche-
matics of the vapor-phase methods presented in this work are
reported in Figure 2.
As afore-mentioned, polymers are conventionally synthetized
in solution processes. In contrast, vapor-phase polymerizations
work in conditions ranging from atmospheric pressure to mild-
vacuum environments, in which the monomers and active
species are not dissolved in a common media, but ﬂown as
vapors and/or gases in the reaction vessel. The polymer is then
formed by the adsorption of the polymer building blocks on the
substrate, which is often kept at low temperature. In other words,
the vapor-phase processes are completely dry.[63]
The way in which the polymer building blocks are formed
from the monomer vapors is what mainly distinguishes the
different vapor-phase processes. Synthetic routes like parylene
polymerization require thermal energy to decompose the
monomer species and initiate the growth of the polymer© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 21)
Figure 1. Schematics of the major advantages of vapor-phase deposition methods applied for the encapsulation of drugs.
www.advancedsciencenews.com www.aem-journal.comchains.[64] Other types of CVD methods are based on the
production of radicals and ions by light irradiation[65] or by
assistance of a plasma discharge.[55] Processes like initiated
chemical vapor deposition (iCVD) make use of a sacriﬁcial
molecule, called initiator, that is, thermally decomposed atFigure 2. Vapor-phase deposition methods applied for the encapsulation
initiated chemical vapor deposition (iCVD), c) atomic/molecular layer deposit
adopted with the relative chemical structure. A complete list of the molecu
Adv. Eng. Mater. 2017, 1700639 1700639 (4relatively low temperatures, at which the monomer units are
stable (Figure 2b).[54] The so-formed radicals selectively react
with the vinyl bonds of the monomer units following the
mechanism of a classical radical polymerization. Therefore, only
monomers bearing vinyl groups can be polymerized by iCVDof drugs: a) plasma enhanced chemical vapor deposition (PE-CVD), b)
ion (ALD, MLD). At the bottom, some examples of monomers/precursors
les reported in this review is presented in Table 1.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 21)
Table 1. Summary of the deposition methods, monomer/precursors
and model drug/molecule investigated with the different strategies
presented in Section 3.
Deposition
method
Monomers/
precursor
Model
drug/molecule Ref.
iCVD Methacrylic acid
Ethylacrylate
Ethylene dimethacrylate
Fluorescein
Ibuprofen
[54]
iCVD Methyl methacrylate
Ethylene dimethacrylate
Camptothecin [73]
iCVD N-isopropylacrylamide
Diethylene glycol divinyl ether
Aminostyrene
Camptothecin [74]
iCVD 2-hydroxyethyl methacrylate
Methacrylic acid
Perfluorodecyl acrylate
Clotrimazole [76]
[78]
PE-CVD Allyl alcohol Acetylsalicylic acid [91]
PE-CVD Tetramethylcyclo-tetrasiloxane Daunomycin
Rapamycin
NPC-15199
[92]
PE-CVD N-heptylamine Levofloxacin [93]
[94]
PE-CVD Acrylic acid
Hexamethyldisiloxane
Methylene Blue [95]
PE-CVD Polydimethylsiloxane
Tetraethyl orthosilicate
Rifampicin [98]
PE-CVD e-caprolactone
2-methoxyethyl ether
Methylene Blue
Cisplatin
[99]
[100]
PE-CVD Air-fed plasma
Diethylene glycol dimethyl
ether
Ampicillin [101]
PE-CVD Tetraglyme Ampicillin [105]
PE-CVD Allylamine Vancomycin [102]
PE-CVD Perfluorooctane Camptothecin [103]
PE-CVD e-caprolactone
2-methoxyethyl ether
Simvastatin acid [104]
PE-CVD Perfluorohexane Ketoprofen [111]
PE-CVD Ethylene Lysozyme [116]
PE-CVD Ethylene Vancomycin
Fluorescein
[119]
PE-CVD Acrylic acid Doxorubicin [120]
PE-CVD Titanium(IV) tetraisopropoxide α-lipoic acid
Heparin
Abciximab
[121]
PE-CVD Helium Doxycycline hyclate [122]
PE-CVD Ar Salicylamide
Theophylline
Diclofenac sodium
[123]
[124]
[125]
PE-CVD Ar
O2
N2
Curcumin [126]
ALD Trimethyl aluminum
Deionized water
Ketoprofen [107]
ALD Trimethylaluminum Acetaminophen [110]
(Continued)
Table 1. (Continued)
Deposition
method
Monomers/
precursor
Model
drug/molecule Ref.
Titanium tetrachloride
Titanium(IV)isopropoxide
Diethylzinc
Deionized water.
ALD Diethylzinc Fluorescein [108]
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Adv. Eng. Mater. 2017, 1700639 1700639 (5and the polymers obtained have a great chemical speciﬁcity and a
predictable chemical structure. During the iCVD process, co-
polymerization occurs due to simultaneous feeding of
the different co-monomers into the reactor. The ratio of the
monomer partial pressures and the saturation pressure at the
substrate temperature (i.e., PM/Psat)
[54] is used as a quantiﬁcation
of the relative mass amount of each component in the reaction
chamber. By varying the PM/Psat ratio, polymers with adjustable
co-monomer ratios can be obtained. This approach allows the
control of the chemical composition and, thus properties of the
deposited polymer, such as cross-linking and solubility, amongst
many others. The total retention of the monomer functionalities
can be a highly desired property for drug encapsulation and
delivery. The polymer functional groups can be used for
immobilization of the drug or for targeted drug delivery (e.g.,
enteric release by pH-responsive polymer encapsulants[66]).
On the other hand, in a polymerization enhanced by plasma
there is no limitation on which monomers can be adopted. In a
plasma discharge, the main sources of fragmentation of the
monomer vapors are electronic collisions, which are non-
selective toward certain types of chemical bonds (Figure 2a). All
the bonds of the gaseous species feeding the plasma can be
fragmented and even polymers of methane can be obtained.[67]
As a consequence, the number of reaction pathways that
monomer species can undergo during a plasma polymerization
is rather large and the chemical composition of the ﬁnal
polymers is difﬁcult to predict.[68] In addition to the fragmenta-
tion in the gas phase, the growing polymer is known to be subject
to positive ion bombardment. This creates rearrangements of
bonds, cleavages of labile groups, and formation of crosslinks
and branches, increasing the number of possible reaction
pathways. To limit the fragmentation of the monomer structures
and the positive ion bombardment, “soft” conditions can be
used, for example, high pressure, low, and often pulsed plasma
power, resulting, as a drawback, in low deposition rates.[69]
Another strategy to reduce plasma damage to the growing
material is to use remote plasmas, in which the polymer is grown
on a substrate not directly exposed to the plasma area. One of the
major drawbacks in using plasma-based techniques is the
possible damage/fragmentation of the drug molecules, when
these are directly exposed to the plasma, which in turn leads to its
deactivation or toxicity. The afore-mentioned soft process
conditions, therefore, have to be adopted in order to keep intact
the drug molecule structure.
Very recently, self-limiting deposition methods have become
an increasingly adopted solution for the encapsulation of drugs.
Polymers or inorganic matrices with very predictable chemical© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 21)
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(MLD)[57] and atomic layer depositions (ALD),[70] respectively.
MLD and ALD methods are based on sequential self-limiting
surface reactions, yielding thickness control at the molecular
level or atomic level for ALD (Figure 2c). The thin ﬁlms are
obtained by exposing the substrate surface to different cycles of
two or more precursor doses alternated with purging gas doses
to remove unreacted precursor molecules from the gas phase
and leave only those that are chemisorbed on the surface. In
MLD, the two precursors are generally organic molecules that
react with each other through coupling reactions. The self-
limiting nature of these reactions leads to a ﬁlm formed by one
molecular layer at the time. In ALD, one precursor is
metalorganic and the other is generally an oxidant (e.g., water
vapor, ozone, or oxygen plasma). The latter serves as oxidant for
the organic component of the precursor and yield a pure oxide
ﬁlm. The self-limiting surface reactions of the MLD and ALD
processes result in very high conformality and sub-nanometer
thickness control, but extremely low deposition ratesa.[71]
Conformality is the efﬁciency of a thin ﬁlm to coat
tridimensional features of the substrate with a uniform
thickness. In the next sections, it will be demonstrated how
this property can be crucial for drug encapsulation and device
fabrication for drug delivery. Generally, high drug loading can
be achieved in cavities or channels of membranes[72] with a
speciﬁc pore size or on nanopillars[73] or nanoparticles.[74] In
these cases, a thin polymer ﬁlm that preserves the topography
of the substrate at the micro and nano-scale can be highly
beneﬁcial. Together with MLD/ALD, also iCVD has shown high
efﬁciency in evenly covering complex geometrical fea-
tures.[63,75] On the contrary, polymers obtained from solution
synthesis often show meniscus formation or de-wetting, liquid
thinning, and other solvent surface tension effects, which alter
the proﬁle of the coating on the substrate. Plasma polymers
have also lower level of conformality than polymers deposited
by iCVD and MLD/ALD, due to some shadowing and border
effects that can alter the growth of the polymer on
tridimensional substrates.
All the above-mentioned vapor-phase processes operate at
low temperatures, with the consequence that also delicate
substrates such as plastic or paper can be easily coated.
Particularly in the ﬁeld of drug encapsulation, this is a great
advantage, since it allows also the coating of thin molecular
layers of drugs, without evaporation due to high processing
temperatures and without inclusion of solvents, with the only
requirement being that the drug needs to sustain the mild
vacuum.[76] Multilayered structures can also be easily obtained
by vapor-phase methods (see Figure 1), since the vapor
deposition does not require to seek and use orthogonal
solvents for the different polymersb.a It is worth mentioning that a faster self-limiting method that
overcomes the very low deposition rate of classical ALD is available, i.e.,
spatial ALD. In this configuration, the precursors are spatially and not
temporally separated, increasing the overall deposition rate. Further
details can be found in the literature.[148]
bHere orthogonal refers to the fact that a solvent might be a good
solvent for one component while an antisolvent for the other.
Adv. Eng. Mater. 2017, 1700639 1700639 (63. Strategies for Drug Encapsulation and
Controlled Delivery
The recent applications of vapor-phase methods in controlling
drug release are following in principle three major strategies,
which are: encapsulation, embedding, and surface modiﬁcation/
activation. Schemes of these approaches are given in Figure 3.3.1. Encapsulation
One basic and most common strategy in controlled drug release
is to encapsulate drugs with layers made from organic (generally
polymers), or inorganic materials. As afore-mentioned, such an
encapsulating shell often acts then as diffusion membrane in
order to have a timed release and/or as protective barrier, which
allows the drug release to occur when speciﬁc conditions are
met[77] (e.g., barrier disintegration at a speciﬁc site in the body).
Several vapor phase techniques have been employed for the
direct encapsulation of drugs or drug loaded media, taking into
account the possibility to treat a vast variety of substrates, such as
solid surfaces, nanostructured/engineered surfaces, particles,
but also on delicate substrates like amorphous drug
ﬁlms[64,66,76,78] or liquid thin ﬁlms.[79]3.1.1. Encapsulant-Controlled Drug Release
Initiated CVD has been the method of choice when the retention
of functional groups was sought, that is, when speciﬁc
functionalities of the polymer such as stimuli responsiveness
are desired.[80–82] Lau et al.[66] investigated the encapsulation of
ibuprofen microcrystals with smart polymers derived from an
iCVD process. Methacrylic acid (MA) was co-polymerized with
different cross-linking agents, namely ethylacrylate (EA) and
ethylene dimethacrylate (EDMA) which then resulted in a pH
responsive polymeric layer system. In order to verify the pH
responsiveness of this iCVD co-polymer, the poly(MAA-EDMA)
was immersed in various pH buffers, and its swelling behavior
was determined by measuring the variation in thickness using
spectroscopic ellipsometry (SE, Figure 4a). SE can be used to
derive the relative change in co-polymer ﬁlm thickness (Δd)
between initial dry ﬁlms (d0) and the ﬁnal swollen ﬁlms upon
immersion in various buffers of distinct pH. At low pH, the co-
polymer showed a limited swelling, keeping a denser matrix
(swelling 5%). When these layers are exposed to higher pH
solutions (pH 6.5–7), an abrupt variation in thickness was
observed and the co-polymer showed signiﬁcant swelling of
more than 30% (Figure 4a). Furthermore, such swelling is
reversible which even allows multiple swelling and deswelling
cycles to be employed.
Differences in swelling behavior can often be used to
selectively release an encapsulated drug when determined
conditions occur, like speciﬁc pH and temperatures, thus
enabling targeting speciﬁc sites or organs in mammals.[77]
In order to verify the effect of swelling on drug release, the
model drug ibuprofen was encapsulated with poly(MAA-
EDMA). Both model systems showed a different release kinetic
when going from acidic to neutral pH. As clariﬁed in© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 21)
Figure 3. Schematics of the strategies for the controlled drug delivery: a) encapsulation, b) embedding, c) surface modification/activation. The polymer
is represented in light blue, while the drug in orange.
www.advancedsciencenews.com www.aem-journal.comFigure 4b and c, the co-polymer, acting as a diffusion barrier,
signiﬁcantly hinders the model drug/molecule release at
low pH, while allowing a faster release when the pH is increased
close to neutral values. It is worth noticing that, with the drug
molecule adopted, differences in its solubility were already
visible at different pH when no encapsulation was present.
As mentioned in the previous section, the possibility to
conformally coat complex tridimensional geometries allows the
engineering of more advanced drug delivery systems. iCVD has
been demonstrated to achieve highly controlled and conformal
layers, coating complex 3D geometries.[83–86] McInnes et al.[73]
adopted iCVD deposited pH responsive polymers for the
encapsulation of nanoporous drug delivery vehicles, that is,
drug loaded porous silicon (pSi). Camptothecin (CPT) was
chosen as the model drug.[87] After ﬁlling the pores of pSi with
the drug, methyl methacrylate (MAA) was then polymerized on
top of such loaded substrates. EDMA was adopted as cross-
linking agent. A schematic of the device is presented in
Figure 5a. As for the encapsulation of ibuprofen, at low pH the
cross-linked ﬁlm will act as diffusion barrier, while at neutral pH
the ﬁlm will allow the diffusion of the drug out of the porous
hosts. Figure 5b shows the release proﬁle of CPT at pH 1.8 and
7.4. In contrast to the ibuprofen microcrystals shown by Lau
et al., the drug release of CPT here from uncoated loaded-pSi was
independent from the pH value of the solution, and about 80%
dissolved within 17 h. It is important to note that CPT is shown to
be a better model substance for getting insights into the
diffusion properties of a speciﬁc coating, since any deviating
property of the buffer solution on the formulation and its drug
release can be solely attributed to the coating. This means that
the samples coated with poly(MAA-co-EDMA) reveals two
signiﬁcantly different drug release proﬁles which can now only
be relatable to the polymer swelling in the different environ-
ments; in 17 h, 10.7% of the drug was released at pH 1.8, while
higher values, 44.5%, of the drug was released at pH¼ 7.4.
The authors also compared the kinetics of drug release for
coated or uncoated pSi. Often, two different regions can be
distinguished in a drug release proﬁle, when the drug-loaded
layer is put in contact with a solvent. A ﬁrst sudden release of
drug is often reported, followed by a zero order kinetics. The
sudden release is then usually reported as burst release.[88] Burst
release leads to a very high initial drug release, and, in turn, local
high concentration, causing often localized irritation, or even
systemic problems and should for most drug formulation be
prevented. Moreover, it reduces the lifetime of the drug release
device, at the same time decreasing the amount of drug that can
effectively be controlled. Again, an iCVD layer can help reducing
burst release, as visible in Figure 5b.When poly(MAA-co-EDMA)Adv. Eng. Mater. 2017, 1700639 1700639 (7is deposited, the burst release was strongly reduced. This effect is
enhanced at lower pH. As a consequence, a slow release might
be achieved in the gastric juice while intestinal ﬂuid might
reduce this less effectively. This reduction was used as a proof for
the possibility of tuning the drug release kinetics as a function
of pH conditions
In a separate study, McInnes et al.[74] investigated also the
fabrication and characterization of a pSi drug delivery vehicle
capped with an alternative polymer, which was temperature-
responsive. Thermo-responsive polymers are a class of smart
polymers characterized by a volume phase transition at a
certain temperature, which causes a sudden change in the
polymer solvation state. Polymers which become insoluble
upon heating have a lower critical solution temperature (LCST).
On the contrary, polymers that become soluble upon heating,
have a so-called upper critical solution temperature
(UCST).[81,89] Poly N-isopropylacrylamide (polyNIPAAm) is
one of the most studied thermos-responsive polymers and it is
characterized by a LCST of 32 C. In their investigation,
McInnes et al. adopted poly(N- isopropylacrylamide-co-dieth-
ylene glycol divinyl ether) (pNIPAAm-co-DEGDVE) and
compared the performance of this with a non-stimulus-
responsive poly-aminostyrene (pAS). Both polymers were
deposited by means of iCVD. In a similar fashion as for the
pH-responsive polymer capped CPT-loaded pSi, the CPTrelease
was observed for the uncoated and coated pSi at two different
temperatures, 37 and 25 C, higher and lower values than the
polymer LCST, respectively. After 16 h, the amount of CPT
released from the pSi coated with pNIPAM-co-DEGDVE was
52.8% at 37 C and 36.1% at 25 C. This points out that more
CPT is released as the polymer collapses. The authors speculate
that, considering the conformal nature of the coatings, the
opening of the pSi pores widens as the polymer contracts,
enabling the drug to diffuse out at a higher rate. This is also
conﬁrmed by the burst release present at the initial stages of the
diffusion, which is higher at 37 C compared to 25 C. However,
the authors give an alternative explanation, that is, the ejection
of CPT molecules close to the pore openings or on top of the
porous layer. The non-responsive polymer polyAS showed no
difference in release kinetics on temperature variation,
conﬁrming that the differences observed with pNIPAM-
co-DEGDVE are attributable to the polymer thermo-responsive
properties.
Next to iCVD, plasma enhanced CVD has also been employed
for the synthesis of protective coatings to target controlled drug
release. Compared to iCVD layers, PE-CVD deposited polymers
generally show a higher degree of cross-linking, due to its
underlying growing mechanism involving radicals and other© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 21)
Figure 4. a) Spectroscopic ellipsometry analysis of iCVD p(MAA-EDMA).
Change in the relative polymer film thickness (Δd) upon exposure to
different pH buffer soaks, normalized to the dry thickness (d0). b)
Controlled ibuprofen release without coating (open symbols) and with the
iCVD p(MAA-EDMA) coating (filled symbols), at pH 1.2 (triangle) and pH
7.4 (circle); c) Time for complete release in different pH buffers for coated
(unfilled bar) and uncoated (filled bar) ibuprofen samples. Reproduced
with permission from ref.[54] Copyright © 2007 WILEY-VCH Verlag
GmbH & Co. KGaA, Weinheim.
www.advancedsciencenews.com www.aem-journal.com(fragmented) reactive species.[55] Furthermore, they show a
better adhesion to the treated substrate, due to the modiﬁcation
of the substrate surface in the initial stages of the plasma
polymerization. However, due to the directionality of the plasma
ions (actively participating in the ﬁlm growth) and the high
reactivity of the (fragmented) radicals, lower conformality can beAdv. Eng. Mater. 2017, 1700639 1700639 (8achieved, limiting their use on high aspect-ratio nanostructured
substrates. Finally, the highly reactive plasma environment can
modify the surface of the treated samples, changing their
chemical nature. It should be noted, that direct treatments of
(bio-)active molecules can, therefore, lead to partial inactivity or
toxicity,[90] which might reduce its applicability.
The ﬁrst work on direct drug encapsulation by means of PE-
CVD was reported in 2005 by Susut and Timmons.[91] In their
work, acetylsalicylic acid (aspirin) microcrystal were coated in a
PE-CVD reactor with plasma polymerized allyl alcohol. In order
to retain the precursor chemical structure and limit the possible
damage of the plasma, a ‘soft’ pulsed PE-CVD approach was
adopted. In this approach, during the deposition, the plasma is
pulsed at regular intervals (duty cycle, DC), allowing the
activation of the depositing species and at the same time limiting
its fragmentation. Moreover, the plasma exposure time on the
treated samples is limited, reducing plasma induced surface
modiﬁcations. An RF duty cycle is generally reported as in
Equation 1.
DC ¼ τon
τon þ τof f ð1Þ
where τon and τoff are the plasma on and off times, respectively.
The polymer properties were investigated as a function of three
processing variables, namely RFpower, coating time and RFduty
cycle. This demonstrates the versatility of vapor-deposited
polymers in general, as many processing parameters can be
adjusted to meet the application-speciﬁc requirements. The
matrix properties can be easily varied and adapted to the system
to encapsulate. Acetyl-salicylic acid release rates were measured
with UV–Vis spectroscopy. The release rates were found to
decrease as the power input, the coating time and plasma duty
cycles are increased. Increasing the coating time leads to higher
thicknesses that slow the out-diffusion of the drug molecules.
The power input and duty cycle act instead on the cross-linking,
which reduces the overall free volume of the polymer, in turn
hindering the drug release. Additionally, in their work thin-layer
chromatography (TLC) was adopted to determine if undesirable
conversion of some drug molecules to other compounds
occurred due to plasma exposure. The TLC results suggest that
negligible amounts of drug molecules are converted to other
compounds during the coating process, showing the feasibility
of pulsed PE-CVD in the direct coating of drug molecules.
Similar conclusions are reported by Zamora et al.,[80,92] where
three different drugs are coated with a plasma organosilicon
polymer. In their work, a direct plasma without any pulse was
adopted. However, the authors do not comment on the stability
of the drugs in the conditions explored.3.1.2. Encapsulant-Controlled Interaction with External
Environment
Together with a better control on the release of active molecules,
encapsulating polymers can be used for changing the surface
interaction with external environments, for example, anti-
fouling chemistry or improved wettability. Vasilev et al.[93,94]
reported on the plasma polymerization of n-heptylamine for the© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 21)
Figure 5. a) Schematics of the pSi coated with the iCVD polymer and the mechanism of release at different pH. b) Drug release curves for CPT from
uncoated pSi and after coating with p(MAA-co-EDMA) at a pH of 1.8 and 7.4. The p(MAA-co-EDMA) coating enabled the controlled pH-dependent
release of the drug from the drug delivery system. Adapted with permission from ref.[61] Copyright (2012) American Chemical Society.
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ultra-thin (10 nm) plasma polymer layer is applied on the surface
of untreated samples (quartz substrates). The role of this layer is
to provide deﬁned surface wettability before the application of
the drug solution, as on some materials insufﬁcient wetting
might cause inhomogeneous spreading. As they report, for the
medical implant materials titanium and polyethylene, drying of
the applied drop of drug solution would likely result in different
shapes and sizes of the drug particles owing to different capillary
forces acting on surfaces with different surface energies. The
drop-casted levoﬂoxacin is then encapsulated with a thicker n-
heptylamine plasma polymer. The authors reported on faster
ﬁrst order kinetics as a function of the loaded amount of the
drug, which in the case studied results in bigger levoﬂoxacin
crystals. In general, smaller particles provide faster dissolution
on account of larger surface area but the reason for a faster
release here has to be attributed to the poor conformality of the
plasma polymer at the crystals surface. Especially, as the crystal
surfaces increased their roughness/nano-structuration, the
coating grows even less conformal and thinner in some crystal
facets, thus allowing for a faster release.[93]
In a similar fashion, Zanini et al.[95] reported on the loading of
a model dye, methylene blue (MB), on polypropylene (PP)
substrate pre-treated with plasma-induced graft polymerization
of acrylic acid (AAc). Due to the presence of carboxylic groups,
PP-AAc ﬁlms immersed in a buffer solution were found to
adsorb one order of magnitude more cationic MB compared to
the untreated PP. The PP-AAc loaded samples were then coated
with a plasma polymer obtained with hexamethyldisiloxane
(HMDSO)-fed plasma. Together with the intrinsic diffusion
barrier properties of the organosilicon polymer, its hydropho-
bicity further enhanced the control over the dye release. Water
diffusion into the layer was hindered, delaying the MB out-
diffusion. Additionally, in order to get further insights into the
kinetics of diffusion, the MB release over time was modelledAdv. Eng. Mater. 2017, 1700639 1700639 (9with the equation proposed by Ritger and Peppas, as reported in
Equation 2.[96,97]
Mt=Mtot ¼ ktn ð2Þ
where Mt is the mass of compound released at any given time t,
Mtot is the total mass of compound loaded, t is the release time, k
is the kinetic constant of the system, and n is a characteristic
exponent for the release. This equation is commonly used to
describe the release kinetics of a compound and agrees only for
the ﬁrst 60% of the mass dissoluted. When n is 0.5, the
compound is considered diffusing with Fickian behavior. For n
of 0.25, the behavior is called Case II diffusion. Finally,
anomalous transport behavior is known as non-Fickian diffusion
and it is intermediate between Fickian and Case II.
For HMDSO-polymer coated PP-AAc, the value of n was
found in the non-Fickian diffusion case (0.73). The authors
explain this behavior accounting for the granular structure of the
HMDSO coatings, in which intergranular pores are relatively
large compared to the model molecule.
A similar sandwich-like structure has been recently investi-
gated by Dowling et al.[98] In this case, atmospheric pressure
plasma CVD was adopted. Polydimethylsiloxane (PDMS) and
tetraethyl orthosilicate (TEOS) were used as organosilicon
precursors. The wettability of the polystyrene substrate toward
the drug molecule under study (Rifampicin) was enhanced by
the deposition of a TEOS-polymer and then capped with PDMS-
polymer. The possibility to achieve hydrophilic surfaces by
means of plasma polymers modiﬁcation could increase the
number of accessible substrates that can potentially be loaded
with drug molecules.
The possibility with vapor-phase methods to easily engineer
multilayer structures is well represented by the works of Bhatt
et al.[99,100] In their investigations, in vitro,[99] and in vivo[100]
studies were performed on pulsed inductive PE-CVD polymers© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimof 21)
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obtained with e-caprolactone (e-CL) in the presence of 2-
methoxyethyl ether (DEGME). The multilayer structure con-
sisted of a buffer layer of poly(DEGME) to increase the surface
hydrophilicity and improve the uniformity of the drug layer.
The drug (cisplatin) or the model molecule (MB) were loaded
on the ﬁrst poly(DEGME) layer. The encapsulation layer
comprised three layers. A ﬁrst PCL-co-PEG layer in direct
contact with the loaded molecules was deposited adopting a soft
pulsed discharge to minimize the possible damage on the
loaded molecule occurring upon plasma exposure. A second
PCL-co-PEG was deposited in continuous plasma mode, in
order to obtain a denser and more cross-linked layer to work as
release control barrier. Finally, a third PCL-co-PEG coating
deposited at mild plasma conditions to obtain a functionalized
layer. This layer was meant to control the biological activities
such as the cell adhesion and proliferation, and cell migration,
on the surface owing to the retention of ether groups available
on the surface of the co-polymer coatings. This multi-layered
system allowed the study of the drug release decoupled from
the cell proliferation, due to the separate roles of the second and
third layer. The kinetics of the drug release was found to be a
function of the layer thickness[99] shifting from a pure zero
order diffusion to a non-Fickian regime concluding from the
Peppas equation (Eq. 2).[96,97]
Furthermore, the in vitro study showed that cisplatin
incorporated with the multilayer coatings had higher cytotoxicity
when compared to cisplatin alone. These results point out that
the third PEG-rich PCL-PEG co-polymer coating offers a surface
with tailorable cell surface interactions without affecting the
barrier layer dependent drug release kinetics.
For the in vivo studies, histological examinations were
performed on liver tissues, which were in contact with cisplatin
loaded plasma polymerized cellophane implants. Hepatocellu-
lar vacuolization and cisplatin induced inﬂammation of cells
were shown. As compared to untreated cellophane implanted
on liver tissues, the apoptotic cells were found to remain in the
liver tissues which were in contact with cisplatin loaded
implants.[100]3.1.3. Encapsulation on Tridimensional Structures
As already discussed for iCVD deposited encapsulating polymers,
vapor-phase methods can attain high level of conformality,
allowing the treatment of complex 3D structures. Despite the
poorer conformality of PE-CVD systems when compared to other
methods such as iCVD and ALD (later discussed), PE-CVD
methods have been successfully used for the treatment of more
complex tridimensional structures. Labay et al.[101] reported on the
treatmentofPPmeshesadoptingatmosphericPE-CVDtreatment.
Pre-treatment of the meshes with air-fed plasma was adopted to
increase the hydrophilicity of the PP surface and, in turn, the
loadingofdrug (ampicillin).APEG-likepolymer is thenadopted to
maintain unchanged ﬁbroblast properties such as chemotaxis or
adhesion with respect to untreated PP meshes. Vasilev et al.[102]
coated vancomycin loaded anodic alumina oxide (AAO) layers
using PE-CVD allylamine polymers. By accurately changing the
plasmapolymerization time, theAAOporewidthcouldbereducedAdv. Eng. Mater. 2017, 1700639 1700639 (1in a controlled way. The drug release was found to scale with the
reduced pore diameter, and the amount of drug subject to initial
burst release decreases with the reduction in the pore opening.
Afterwards, zero order release was found and attributed to drug
positioned deeper in the pores. Also the example discussed in
section 3.1.1 (Figure 5), falls in the category of encapsulation on
tridimensional structures (pSi). Furthermore, also porous silicon
microparticles (pSi-MP) were treated with a perﬂuorooctane
(PFO)-fed plasma polymer by McInnes et al.[103] The successful
loading of the drug (camptothecin) and subsequent coating of the
loaded pSi-MP is demonstrated. The coating is shown tomarkedly
slow down drug release, which can be further adjusted by altering
the plasma deposition time. 2-fold to 100-fold slower drug release
is demonstrated, conﬁrmed by in vitro experiments. Human
neuroblastoma showed delayed cell death for all coated particles.
Other more complex 3D structures have been treated with PE-
CVD methods. Calcium phosphate (CaP) scaffolds loaded with
drugs were used as substrates for PE-CVD polymers by Canal
et al.[104] and Labay et al.[105] Canal et al. reported on the
treatment of two different scaffolds, Calcium Deﬁcient
Hydroxyapatite (CDHA) or high-temperature sintered β-Trical-
cium Phosphate (β-TCP), characterized by different available
surface areas and porosity (Figure 6).[104] Simvastatin acid (SVA)
was incorporated to the CaP scaffolds. The authors deposited
biocompatible PCL-co-PEG by means of PE-CVD on both CaPs
and investigated the polymer thickness and coated depth as a
function of the different available surface areas. The study shows
that this coating signiﬁcantly changed the surface topography of
the CaPmaterials, leading to the formation of bush or worm-like
structures (Figure 6). Furthermore, when the coating was able to
grow deep into the scaffold (β-TCP), the release of the loaded
drug was completely hindered. Contrary, when the coating grew
only on top of the 3D structure (as in the case of the CDHA
scaffold), the drug release occurs and is found scalable with the
coating thickness, in agreement with the previous ﬁndings using
the same plasma treatment.[99]
Labay et al.[105] deposited PEG-like coatings on β-TCP using
diglyme as precursor in the plasma process. The scaffolds were
previously loaded with ampicillin and release experiments were
carried out as a function of the plasma process parameters. It is
worth noticing that the biological activity of ampicillin was also
reported after plasma polymerization. The antibiotic showed a
retention of its activity, conﬁrming the non-signiﬁcant impact
the plasma treatment has on loaded drugs, also when supported
on complex 3D structures.
Next to polymer encapsulation, very recently vapor-phase
deposited metal-oxides have been adopted as drug release
barriers, either directly deposited on the drug crystals[106] or on
drug loaded polymers.[107,108]Atomic layer deposition (ALD) has
been the method of choice for the deposition of ultra-thin
conformal metal oxides, showing promising results in terms of
controlled release which might differ from those obtainable
from organic derived layers. As afore-mentioned, ALD is an
effective method for the coating/surface modiﬁcation of high
surface area and highly porous materials. Due to the diffusive
and self-limiting nature of its growth mechanism, this
technique allows for sub-atomic control of layer thickness, in
this being superior to the other vapor-phase methods. Vogel
et al.[107] reported the treatment of poly(vinyl alcohol) (PVA)© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim0 of 21)
Figure 6. SEM images of the different materials before (top images) and after plasma polymerization with PCL-PEG (4:1). a) β-TCP, b) CDHA, c) β-TCP-
90CW, and d) CDHA-90CW. FIB-SEM cross-section of the surface of both polymerized materials β-TCP-90CW e) and CDHA-90CW f). CW refers to
continuous wave plasmas. Reproduced with permission from ref.[92] © 2016 Elsevier Ltd.
www.advancedsciencenews.com www.aem-journal.comelectrospun nanoﬁbers loaded with a small molecule drug,
ketoprofen, with ALD Al2O3. The morphology and drug release
were monitored as a function of the ALD Al2O3 thickness,
ranging from 2 cycles to 200 cycles (Figure 7). The authors do
not report a speciﬁc growth per cycle (GPC) for the ALD
process. However, a thickness <30 nm was sought. Remark-
ably, only 2 cycles of ALD Al2O3 (corresponding approximately
to 0.2–0.3 nm) were found sufﬁcient to reduce the ketoprofen
release from 2min (uncoated) to 24 h (coated with 2 cycle ALD
layer). Increasing the thickness of the layer, a control
over the release kinetics was achieved. The effect of
the treatment on the PVA ﬁbers and ketoprofen is also
investigated. The melting point of the PVA ﬁbers was found to
decrease for the ﬁrst 2 ALD cycles and then was found constant
regardless the thickness of the ALD layer, indicating a surface
interaction of the ALD layer with the PVA polymeric chains.
However, the ketoprofen integrity was found to be retained
upon the ALD treatment, as pointed out by UV spectroscopy of
the released drug molecules.
Very recently, Ka ̈a ̈ria ̈inen et al.[106] reported on a thorough
investigation on the direct encapsulation of acetaminophen
crystals by different ALD metal oxides, namely Al2O3, TiO2,
and ZnO. In this study, the effect of the ALD process on the
drug morphology is studied, together with the delayed release
and cytotoxicity of the ALD coatings. The ALD process was
found not to signiﬁcantly degrade acetaminophen crystals.Adv. Eng. Mater. 2017, 1700639 1700639 (1TiO2 deposited by means of TiCl4 was found to locally modify
the crystal structure of the drug molecule, due to the
formation of a binary system between TiO2 and acetamino-
phen. Furthermore, scanning electron microscopy (SEM) and
energy dispersive spectroscopy (EDS) revealed a uniform ALD
coating on the drug crystals, conﬁrming the feasibility of this
process also for the direct encapsulation of drugs. Finally, the
cytotoxicity analysis showed the cyto-compatibility of the TiO2
layer, contrary to the ZnO layer which showed a higher
cytotoxicity.3.1.4. Encapsulant-Controlled Drug Morphology
Next to the control on the drug release and the possibility to
tune the surface chemistry, encapsulation of drugs has been
investigated for improving the stability of speciﬁc drug
morphology. Considering the formulation of drug systems,
poor solubility and low bioavailability often represent a hurdle,
hindering their applicability. One of the approaches to
overcome poor drug solubility is the use of amorphous solid
state drugs. In the amorphous state, the higher accessible
surface and the lack of lattice energies result in excess free
energy. Consequently, the energy involved in the solubilization
process is relatively low compared to crystalline systems.[109,110]
In order to keep the drug molecules in an amorphous state and© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1 of 21)
Figure 7. SEM micrographs of 7wt% PVA electrospun mats coated with a) 0 cycles, b) 2 cycles, c) 20 cycles, and d) 200 cycles of Al2O3 ALD chemistry.
On top, a schematic of the ALD process on the PVA fibers. Reproduced with permission from ref.[95] © 2015 WILEY-VCH Verlag GmbH & Co. KGaA,
Weinheim.
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mobility and water vapor exposure need to be achieved. The use
of barrier layers has been considered in order to delay the
crystallization and, in turn, dry, single step methods like vapor
phase processes represent a valid approach. In this regard,
Bosselmann et al.[111] performed pulsed PE-CVD on rapid
frozen ketoprofen (RF-KET). Fluorinated coatings obtained
from perﬂuorohexane-fed plasma were adopted in order to
provide a physical and at the same time hydrophobic barrier
coating capable of inhibiting crystallization of an amorphous
drug/polymer system. The stability of the RF-KETupon plasma
exposure is conﬁrmed by the absence of degraded drug
molecules in high performance liquid chromatography
(HPLC). Moreover, the morphology of the drug molecule in
its amorphous state was preserved during the pulsed PE-CVD
process, as shown by differential scanning calorimetry (DSC).
The amorphous drug molecules coated with the hydrophobic
plasma polymer were shown to keep their amorphous
morphology up to 6 months after encapsulation when stored
at a temperature close to the drug molecule glass temperature
and in high relative humidity. The uncoated RF-KET showed
instead crystallization after 3 days. Despite the excellent barrier
properties shown by the hydrophobic coating, drug release
experiments showed a poor control over the out-diffusion of
RF-KET. The authors attributed this behavior to the poor
adhesion of the ﬂuorinated polymer on the hydrophilic drug
surface.Adv. Eng. Mater. 2017, 1700639 1700639 (1Encapsulation of amorphous drugs has been investigated in
details also with iCVD polymers by Christian et al.[76,78] Three
different polymer compositions were deposited by iCVD on top of
amorphous clotrimazole ﬁlms to study the stability of the drug
solid state: two different stimuli-responsive polymers, poly(2-
hydroxyethyl methacrylate) [p-HEMA], hydrogel, and poly-(meth-
acrylic acid) [p-MAA], pH-responsive, and a non-responsive
hydrophobic ﬂuorinated polymer, poly(perﬂuorodecyl acrylate)
[p-PFDA].[76] In their study, the authors compare the effect of
different polymer chemistries on the stability of the amorphous
clotrimazole bymeans of optical microscopy and X-ray diffraction
(Figure 8a). Storage of the samples at ambient temperature, 50 and
70 C showed that hydrophilic polymers such as p-HEMA and p-
MAA are able to keep the amorphous state of the drug. p-PFDA,
instead, due to its hydrophobic nature and intrinsic crystallin-
ity,[112] showed complete crystallization of clotrimazol already at
50 C. In-situ X-ray diffraction as a function of temperature
conﬁrmed these results, showing that p-HEMA and p-MAA
prevent clotrimazole crystallization throughquickheat treatments
up to themelting point of the crystalline drug (Figure 8b). Finally,
wrinkle formation upon the deposition of the iCVD polymers has
been reported in thiswork, due to differences in elastic behavior of
the drug layer and the polymer. An extended study has been
reported in a follow-upwork (Figure 8c).[78] Suchwrinkles are very
promising as these might allow the construction of surface layers
of signiﬁcantly larger surface area, which often helps faster drug
release.© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim2 of 21)
Figure 8. a) X-ray diffraction scans of clotrimazole encapsulated with different polymers (p-HEMA, p-MAA, p-PFDA) after storage at different conditions;
b) In-situ X-ray diffraction scans of amorphous clotrimazole films, encapsulated by iCVD layers, at different temperatures. Reproduced with permission
from ref.[64] © 2016 American Chemical Society. c) AFM height images of pHEMA films coated on top of clotrimazole spacing layers of varying
thicknesses, as reported in the labels. Reproduced with permission from ref.[66] Published by The Royal Society of Chemistry.
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As afore-mentioned, solubility and bioavailability of drug
molecules represent a major challenge for their use in
medication. One possible strategy, next to the encapsulation,
is the formation of the so-called solid molecular dispersions or
solid solutions. In this approach, the drug is dispersed in an
(usually hydrophilic) inert solid matrix in order to enhance the
drug solubility during application. Additionally, control over
the dissolution rate can be achieved by choosing a speciﬁc
chemistry or cross-linking degree. Numerous studies on solid
dispersions have been published and showed the advanta-
geous characteristics of solid dispersions in improving the
solubility and dissolution rate of poorly water-soluble drugs.
However, long-term stability problems, for example, drug
crystallization and decrease in dissolution rate, have been
reported, due to the complexity of the methodology used toAdv. Eng. Mater. 2017, 1700639 1700639 (1obtain the solid dispersions. Detailed insights into the subject
can be found in the literature.[113,114] Vapor-phase methods
have been recently adopted for the engineering of solid
dispersion, either in single-step processes[115–117] or for
the further stabilization of drug-matrix dispersions.[108] The
literature mostly reports on strategies for active biological
compounds added as a second step to vapor-phase deposited
substrates. This second step is often carried out through
the adsorption of the drug/bio-active material in solution
processes.[118]
A novel method for the inclusion of drug molecules has been
demonstrated by Palumbo et al.[116] A one-step spray-assisted
atmospheric- pressure plasma process for the synthesis of solid
dispersions is investigated. Lysozyme (Lyz) dispersed in water is
sprayed in the plasma reactor chamber together with a helium
ﬂow. Ethylene-fed plasma is used in order to deposit a
hydrocarbon matrix. Water-droplet encapsulated Lyz molecules© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim3 of 21)
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ethylene monomers begin to dissociate, polymerizing into
polyethylene-like (PE) coating. At the same time, Lyz molecules
start to deposit intact on the substrate, due to the protective
action of the water droplets. The droplets dissociate and vaporize
due to discharge and gas heating, allowing the embedding of Lyz
into the polymer matrix.[117] The amount of embedded Lyz was
controlled by process parameters, as clearly evidenced by IR
spectra in Figure 9a.
The retention of the Lyz structure is a crucial parameter for
the assessment of the deposition methodology. MALDI-TOF
(Figure 9b) and HPLC were used for the determination of the
embedded and released Lyz, respectively. The two analyses point
out that the majority of embedded Lyz retained its structure.
Broadening of the peaks indicated minor changes in the
embedded molecule structure. Nevertheless, its activity is
maintained, as pointed out by an Agar diffusion assay.
With a similar approach, Vancomycin was embedded in a PE
matrix.[119] Remarkably, the polymerized layers were comprised
of spherical features with nanometric size (Figure 10a). In order
to get further insights into the nanocapsules’s structure,
vancomycin was replaced with ﬂuorescein in the aerosol
solution and analyzed with confocal microscopy (Figure 10b).
From the images, spherical structures, hundreds of nano-
meters wide, have been identiﬁed consisting of a hydrocarbon
polymeric shell and a vancomycin/ﬂuorescein containing core.
By varying the plasma parameters, it is possible to tune the
dimensions and the aggregation of the nanocapsules. These
structures seem to release the contents of their cores after
immersion in water.[119]Figure 9. a) FTIR spectra of: casted Lyz (a); films deposited at an atomizer flow
slm atomizer flow rate, but with a 8mgmL1 Lyz solution (f). b) MALDI-TOFm
with permission from ref.[104] © 2015 WILEY-VCH Verlag GmbH & Co. K
Adv. Eng. Mater. 2017, 1700639 1700639 (1Modiﬁcation of a pre-loaded polymer is an alternative route
for the embedding of active molecules. ALD has been adopted
for the synthesis of hybrid organic-inorganic blends containing
the model molecule ﬂuorescein.[108] Films of PEG 400, a liquid
polymer at room temperature, were converted into a solid
hybridized ﬁlm by means of ALD. ALD zinc oxide was deposited
on top of ﬂuorescein-loaded PEG and found able to penetrate
deep into the polymer (Figure 11). ZnO was formed within the
bulk of this gel like ﬁlm. While PEG works as loading medium,
the subsequent ALD process converts the liquid drug-solution
into a solid hybrid layer, forming the storage phase. A release
layer (poly(3,4-ethylenedioxythiophene), PEDOT) is added on
top of the PEG-ZnO, serving as gate keeper, for the engineering
of a releasing device, as it will be discussed further in the review.3.3. Immobilization/Surface Modification
Vapor-phase methods are also adopted for the deposition of
buffer layers and subsequent (covalent) immobilization of drug
molecules or, when plasma based techniques are used, these
techniques are applied for the surface modiﬁcation of polymeric
matrices adopted as substrates.
Myung et al.[120] reported on the immobilization of
doxorubicin on the surface of plasma polymerized acrylic acid.
The presence of carboxylic groups retained during plasma
polymerization enhances the loading of the drug molecule and
allows, already without encapsulation layer, a slower release of
the drug. In a similar fashion, enhanced drug loading can be
achieved by modifying the polarity of the surface, either withrate of 0 (b), 3 (c), 4 (d), 5 slm (e) with a 5mgmL1 Lyz solution; and at 5
ass spectra of native lysozyme (a) and the HiLyz sample (b). Reproduced
GaA, Weinheim.
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Figure 10. a) Top view SEM images (extraction voltage of 2 kV) of the continuous wave (CW) sample before immersion at 10 k (A) and 50 k (C), and
after 60min of immersion in water at 10 k (B) and 50 k (D). b) Confocal microscopy images: top view reflection (A) and top view fluorescence (B),
section reflection (C) and section fluorescence (D) of the nano-capsules deposited in CW mode, feeding the aerosol with fluorescein. A scheme of the
hypothesized core–shell structure for vancomycin and fluorescein containing nanocapsules is shown (E). Reproduced with permission from ref.[107]
This journal is © The Royal Society of Chemistry 2017.
www.advancedsciencenews.com www.aem-journal.complasma polymerization or with grafting/surface modiﬁcation of
samples. As afore-mentioned, Bahtt et al.[99] adopted this
approach to homogenize the loading of the drug molecules on
the substrate and increase the amount loaded. Song et al.[121]
reported on the surface modiﬁcation of bare metal stents by
means of PE-CVD. TiO2 layers were obtained by plasma
treatment of titanium(IV) tetraisopropoxide (TTIP) and
subsequently further functionalized by water-fed plasma. This
last step introduced hydroxyl groups on the TiO2 surface,
allowing the grafting of drug molecules. α-lipoic acid (ALA),
heparin, and abciximab were successfully immobilized on the
stent surface.
Labay et al.[101] investigated the effect of atmospheric plasma
treatment of PP meshes, as mentioned in the previous
paragraph. The plasma treatment was found to drastically
modify the morphology and surface chemistry of the meshes.
Hydrophilic surfaces (contact angle 20) and high surface
roughness were measured after plasma treatment (Figure 12).Adv. Eng. Mater. 2017, 1700639 1700639 (1Upon loading of the PP meshes with ampicillin, a signiﬁcant
increase in the loaded amount when compared to untreated
samples was reported. Short treatment times showed a 2-fold
increase which can be attributed to the improved surface
wettability, while longer times loaded up to 3-fold the weight
percentage obtained by the untreated PP. The higher loading at
higher plasma treatment times was attributed to the additional
grafting of new C–O bonds and the major available surface area
given by the higher roughness.
Canal et al.[122] evaluated the surface modiﬁcation of
microporous β-TCP scaffold ceramics with He-fed atmospheric
pressure plasma jet (APPJ) for the design of controlled release
matrices. The plasma treated microporous β-TCP ceramics have
been loaded with doxycycline hyclate. The authors show that the
treatment with the atmospheric plasma needle using He led to a
progressive increase in oxygen content with longer treatment
times. Moreover, charging of the surface develops, inﬂuencing
the loading of the drug molecules. It is showed that the© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim5 of 21)
Figure 11. a) Spin-coating of a drug-containing PEG film (green) onto the substrate, followed by the formation of a hybrid structure by means of ZnO-
ALD in “yellow”. Last, coating with conducting polymer layers (blue). b) Cross-sectional Scanning Electron Microscopy (SEM) image of the PEG/ZnO
release system. The hybridized storage layer is marked in green (middle) with the primary conducting polymer layer on top, represented in blue. The
process is schematized on the left side of the image. Reproduced with permission from ref.[96] Copyright© 2016, Rights Managed by Nature Publishing
Group.
www.advancedsciencenews.com www.aem-journal.comhydrophilic surface and charge developed are able to slow down
the release of the loaded drug, achieving more than 33%
improvement in retaining drug release for optimized APPJ
treated β-TCP with respect to untreated samples.
Finally, plasma treatment can be used to induce higher cross-
linking degree on pre-loaded polymers. In a series of studies on
the effect of inert gas fed-plasma treatment on polymer
structure, Yamahuci et al.[123–125] investigated the treatment of
polymer powders[123] or direct treatment of preloaded drug-
polymer tablets[124,125] Cross-linking of the polymers’ outer
shell backbone leads to a pseudo-encapsulation effect,
decreasing the drug release rate. Similar conclusions have
been achieved by Hagiwara et al.[126] in treating curcumin-
loaded poly(ethylene-co-vinyl acetate) with different plasma
environments (O2, N2, Ar).4. Conclusions and Outlook to Future Device
Fabrication
Drugdelivery, targeted to a speciﬁc body location and/or in time, is
an interesting feature of the new generation biomedical devices
and it can be achieved through the use of “smart” formulation
embedded in tunable polymer shells that hinder the drug releaseAdv. Eng. Mater. 2017, 1700639 1700639 (1until a proper stimulus is detected.[127] Stimuli-responsive
polymers serve this purpose very well: they undergo changes in
thickness, mesh size and/or surface energy depending on the
external stimuli, like temperature,[128] pH,[66,64] and light.[52,129]
Summarizing the previous paragraphs, the deposition of this kind
of polymers from the vapor phase can have several advantages: (i)
the absolute lack of solvents or high temperature allows easy drug
encapsulation, without inducing damages that would harm the
formulation or components therein and later the therapeutic
effects; (ii) the absence of plasticizers, leachable, and surfactants
eliminates the health considerations associated with these
components; (iii) the possibility to reproduce interesting geome-
tries by conformally coating the tridimensional features of a
substrate; (iv) the easy tunability of theﬁlmand surface properties.
Surface modiﬁcations that yield a large density of functional
groups can be used to tether biomolecules (e.g., proteins, DNA
fragments) to drug delivery devices in order to detect biological
entities like bacteria and viruses andhave very speciﬁc therapeutic
actions.[130] In the previous sections, different strategies were
presented for loading a drug within/beneath a polymer deposited
from the vapor phase. These drug-loaded polymers were then
successfully integrated in several delivery devices for therapeutic
dosing. In the next section, vapor deposited polymers are
presented together with some examples of devices where the© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim6 of 21)
Figure 12. PP fiber modified by a first plasma treatment aimed at increasing the adhesion of drug molecules, followed by a second plasma deposition of
a PEG polymer. The process is schematized on top of the figure. AFM topography (top images) of the untreated (UT) a), air-plasma treated for 3.5 s
(F-3.5 s) plasma-treated b) PP meshes, and after PEG plasma coating: UTþPEG c) and F-3.5 sþPEG d), with the respective 3D reconstitutions of the
fiber surface (bottom images). Reproduced with permission from ref.[89] © 2015 Elsevier Ltd.
www.advancedsciencenews.com www.aem-journal.comuse of advanced growthmethods could be highly beneﬁcial for the
future generation.
Devices based on stimuli-responsive polymers. Burst release of
ﬂuorescein was demonstrated by a device made of coaxial
nanotubes consisting of a shape-memory shell and a hydrogel
core.[131] The swollen hydrogel was loaded with the dye and dried
to deswell. At high temperature, the shape-memory shell shrank,
squeezing the dye out of the structure. Both the hydrogel core
and the shell were deposited by iCVD, by sequential depositions
of the two polymers into the pores of an anodized aluminum
oxide membrane. Thanks to the conformality of the iCVD
process, coaxial structures at the nanoscale were obtained,
resulting in an effective burst release. Fluorescein was used as a
model molecule in this study, for easy monitoring by opticalAdv. Eng. Mater. 2017, 1700639 1700639 (1spectroscopy. Nevertheless, the same principle could be used for
burst release of drugs upon the correct stimuli.
Stimuli-responsive polymers were also used to regulate the
ﬂow of drugs through microﬂuidic devices.[132] Baldi et al.
showed a microﬂuidic system made of a combination of hard
and soft materials. In this case, a glucose-sensitive hydrogel
controls the ﬂow of insulin in response to changes in glucose
concentrations.[133] When the hydrogel expands, upon changes
in glucose concentration, it closes down the ﬂow inlet so insulin
cannot be delivered.
Also light can be used as external stimulus to trigger delivery,
for example, on skin patches. Light-responsive polymers, as the
one synthetized by Pauly et al.[129] have chromoforic groups like
spiropyran tethered to the polymer backbone. The light induces a© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim7 of 21)
www.advancedsciencenews.com www.aem-journal.comreversible hydrolysis in the spiropyran moieties, changing the
wettability and the permeability of the polymer. An enhanced
ﬂow of caffeine was registered through the polymer membrane
when this was exposed to light.
Devices based on electrochemical stimuli. Next to responsive
systems, also devices based on electrochemical triggering have
been shown to have several interesting features especially for
transdermal delivery. Boehler et al. showed an example of a
promising device in which the drug delivery, upon electrical
stimulus, was coupled with enhanced drug storage within a
hybrid material made of ZnO and polyethylene glycol.[108] As
described in the previous section, the polymer served as
dispensing medium for the liquid drug, which was then
solidiﬁed by deposition of ALD ZnO. This hybrid layer could
store up to 25 ng of drug in a few micron thicknesses. The
delivery was achieved by applying a voltage to the conductive
polymer that was added on top of the hybrid structure. Negative
bias triggered the release while positive bias suppressed it.
He et al.[134] showed another example of electrochemically
triggered drug delivery interfaces based on a ﬂexible electrode
consisting of thin gold ﬁlms, deposited onto Kapton, coated with
doxorubicin-loaded reduced graphene oxide. The release in this
system was driven by a positive potential bias that decreased
the pH close to the electrode surface and enhanced the
desorption of the drug.
Devices that deliver drugs with a spatiotemporal resolution
upon stimuli can pave the way toward future biochemically
regulated therapeutics reservoirs or “portable pharmacies”. An
early example of such device is shown in Figure 13a. It is a
neurotransmitter delivery device with individually controlled
delivery points.[135] By applying local pulses, the neurotransmit-
ter acetylcholine was delivered independently from the different
delivery points with a temporal resolution of 50ms from the time
of voltage on to the delivery.
Multilayer devices. Steady delivery over extended period of time
can be important for therapeutic dosing of the drug. Dowling
et al. demonstrated a drug eluting system based on a multilayerFigure 13. a) Top-view of an electrically controlled chemical delivery circuit
delivery points within tens of milliseconds. Reproduced with permission from
glucose sensor encapsulated in a pHEMA/EDGA shell deposited by iCVD. R
2011, The Authors.
Adv. Eng. Mater. 2017, 1700639 1700639 (1in which the drug was sandwiched between two plasma
polymers.[98] The role of the upper layer was to restrict the
elution rate, resulting in a signiﬁcantly retarded release over a
7 days period. Another multilayer device was demonstrated by
Bhatt et al.[99] In this case, the drug was sandwiched between a
cell-repellent top layer and a diffusion barrier layer that would
regulate the drug elution. The cell-repellent layer promoted
uninterrupted drug release.
Devices for transdermal delivery. Strategies for transdermal drug
delivery are currently under investigation to expand the library of
drugs that can be delivered through the skin. Currently, due to
the barrier properties of the human skin only very small and
lipophilic drugs can be delivered through external patches.
Microneedles that puncture only the most superﬁcial layer of the
skin would be a pain-free solution that would allow the delivery
of many more pharmaceutics.[136] Overlaying a coating from the
vapor phase that would keep the microneedle shape but add to
the needle material some interesting surface properties (e.g.,
functional groups for biomolecule immobilization) would
augment the functionalities achievable by such delivery systems.
An early example of surface modiﬁcation of microneedles was
shown by Nair et al.[137] They treated the surface of plastic
microneedles with an oxygen plasma to enhance the wettability
of the needle surface toward different drug formulations. As
demonstrated here, depositing thicker layers made from
polymers even would allow introducing additional functionality
from which this very application would deﬁnitely beneﬁt, for
example, hydrogel formation on contact with skin  ﬂuid would
weaken the mechanical strength so that pain sensation would
minimize.
Next to the implementation of existing encapsulating
solutions into working and ‘smart’ devices, new deposition
methods could be used in order to encapsulate/embed drug
molecules into organic or inorganic matrix. As mentioned in
Section 2, molecular layer deposition is, next to ALD, a self-
limiting layer-by-layer vapor phase deposition method that
allows the deposition of fully organic or hybrid organic-inorganic, where charged compounds can be released independently from several
ref.[123] Copyright© 2016, The Authors. b) First in-vivo test of an injected
eproduced from Reproduced with permission from ref.[135] Copyright ©
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim8 of 21)
www.advancedsciencenews.com www.aem-journal.commaterials. The range of polymers that can be deposited by MLD
has rapidly broadened in the last years, together with the
different functionalities that can be implemented. Polyamine,
polyurea and polyesters are only few examples of the classes of
polymers that can be synthesized with this method. Further-
more, a new class of materials, so called ‘metalcones’, hybrid
organometallic polymers, represents an additional possibility. In
the literature, complete reviews summarizing the different
possible polymers are available.[57,138,139] Although still no
examples of encapsulated drug are present in the literature by
MLD deposited polymers, the potential impact of this technique
in the ﬁeld is remarkable. MLD thin ﬁlms have already been
applied as organic interlayer in moisture permeation barrier,[140]
Cu-barrier diffusion layers,[141] photoactive passivation
layers,[142] and as stabilizers during metallic nano-particles in
reforming conditions.[143] Moreover, sharing the same con-
formality and sub-nm thickness control shown by ALD, also the
coating of complex tridimensional structures has been demon-
strated, together with the possibility to change the surface
chemistry to improve wettability and stability.[144]
One of the future challenges that can be envisioned for
vapor-deposited polymers is to surpass all the regulations that
would allow their use in human body. Indeed, when the
polymer shell is non-toxic and biodegradable and the
degradation products are biocompatible and pharmacologically
inactive, the targeted delivery systems can be directly injected
into the body. An injectable hydrogel was proposed by Jeong
et al. made of blocks of poly(ethyleneoxide) and poly(L-lactic
acid).[145] In this case, the bioactive molecules entrapped in the
polymer matrix was released in the body at ﬁrst by diffusion,
and later by the combination of both diffusion and degradation
mechanisms. Similarly, a biodegradable hydrogel was function-
alized with protoporphyrin as a ﬂuorescence tag to track the
drug delivery in-vivo by multispectral ﬂuorescence imaging in
nude mice.[146] Preliminary in-vivo tests of vapor-deposited
polymers for drug delivery already exist (e.g., an optode sensor
was encapsulated in a pHEMA-EGDMA shell by iCVD and
injected into rats,[147] as reported in Figure 13b, but more
demonstrations are required for the signiﬁcant implementa-
tion of vapor deposited polymers in the next generation of
biomedical devices.
In summary, the deposition of polymers from the vapor phase
offers versatile strategies for targeted drug delivery, such as the
absence of solvents, the low process temperature, the possibility
to tailor the physical-chemical properties of the processed layer
in a single synthetic route, and of combining different processes
to achieve multi-layered and, in turn, multi-functional polymers,
overcoming some of the drawbacks of classical encapsulation/
embedding methodologies. Continued implementation of these
polymers in future devices will have a signiﬁcant impact on the
next generation of therapies.Acknowledgements
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